Idiopathic pulmonary fibrosis (IPF) is a progressive and advanced lung disease for which there is no effective treatment at present. The main features of IPF include the damage to the lung epithelial cells along with the excessive depositing extracellular matrix (ECM) secreted from the activated lung fibroblasts and myofibroblasts, whereby leading to reduced air exchange and then impaired lung function. Interleukin-6 (IL-6), which is produced from immune cells, is rapid for response to the tissue injury and has a broad impact on cellular processes such as acute reactions, hematopoiesis, and immune responses. Additionally, elevated levels of IL-6 have been found in various chronic inflammatory diseases characterized by fibrosis and IL-6 plays an important role via activation of Janus kinases/signal transducers and activators of transcription 3 (JAK/STAT3) signaling in the fibrosis of any organ system. Here, we explore the role of IL-6 in pulmonary fibrosis and then providing a therapeutic approach for alleviating the development of pulmonary fibrosis disease and improving the resolution of pulmonary fibrosis damage.